Ultrapotent compound may help treat C. diff, reduce recurrence
Purdue University reported that their researchers have advanced novel compounds that they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Prevention. Their work is published in the Journal of Medicinal Chemistry.
Clostridioides difficile, or C. diff, is the leading cause of healthcare-associated infection in the U.S. Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence.
“Our compounds have several advantages, including ultrapotent activities with minimum inhibitory concentration values as low as 0.003 μg/mL,” said Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry. “Our compounds also do not kill good bacteria at concentrations that kill C. diff and performed significantly better than current antibiotics in preventing recurrence. These are significant advantages for patients dealing with this difficult bacterial infection.”
The most promising of the Purdue compounds, containing trifluoromethylthio functional group, is HSGN-218. Sintim said it has been shown to be one of the most potent compounds ever produced for use against C. diff.
“This is part of our work to create new solutions to treat diseases and infections that are resistant to current treatment options,” said Sintim, who is a member of the Purdue University Center for Cancer Research and the Purdue Institute for Drug Discovery. “This work provides a potential clinical lead for the development of C. diff therapeutics and also highlights dramatic drug potency enhancement via halogen substitution.”
The researchers patented their compounds through the Purdue Research Foundation Office of Technology Commercialization, which is looking for partners to advance the technology. George Naclerio, a researcher on Sintim’s team, has been awarded a National Institutes of Health T32 training grant to help facilitate the development of this technology.
